Intellipharmaceutics Announces Downgrade to OTC Expert Market

2 weeks ago

TORONTO, ON / ACCESSWIRE / June 14, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI.H) ("Intellipharmaceutics" or the "Company"), announced…

Pharma-Bio Serv Announces Results for the Quarter Ended April 30, 2024

2 weeks ago

DORADO, PUERTO RICO / ACCESSWIRE / June 14, 2024 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a…

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement

2 weeks ago

HOUSTON, TX / ACCESSWIRE / June 14, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company…

Bausch Health Reports Promising R&D Trial Updates on Amiselimod and Scientific Data Presented at International Healthcare Conferences

2 weeks ago

LAVAL, QC / ACCESSWIRE / June 14, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global diversified pharmaceutical company enriching…

Medical Equipment Maintenance Market: Forecasted USD 88.9 Billion by 2029, CAGR 10.5% | MarketsandMarkets™

2 weeks ago

CHICAGO, June 14, 2024 /PRNewswire/ -- Projected to grow at a CAGR of 10.5%, the global medical equipment maintenance market…

Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform

2 weeks ago

The Company expects that the application for OTC clearance will shortly be followed by pursuit of POC clearance, with other…

Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)

2 weeks ago

Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few…

Senator Jon Ossoff and Vision to Learn Founder Austin Beutner Address National Vision Care Crisis Among School Children

2 weeks ago

More than 3 million public school children lack the glasses they need. Vision To Learn has helped over 150,000 Georgia…

Avinger Announces Pricing of up to $24 Million Public Offering

2 weeks ago

$6 million upfront with up to an additional $18 million of aggregate gross proceeds upon the exercise in full of…

Ainos Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA

2 weeks ago

Clinical trials for AI Nose-powered Ainos Flora device moves forward with 75 meaningful case results, paving the way for next-gen…